Optipharm.CO.LTD (KQ:153710) — Market Cap & Net Worth
Market Cap & Net Worth: Optipharm.CO.LTD (153710)
Optipharm.CO.LTD (KQ:153710) has a market capitalization of $51.60 Million (₩76.14 Billion) as of May 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21761 globally and #1417 in its home market, demonstrating a -4.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Optipharm.CO.LTD's stock price ₩5190.00 by its total outstanding shares 14669958 (14.67 Million). Analyse Optipharm.CO.LTD (153710) cash flow conversion to see how efficiently the company converts income to cash.
Optipharm.CO.LTD Market Cap History: 2018 to 2026
Optipharm.CO.LTD's market capitalization history from 2018 to 2026. Data shows change from $91.36 Million to $51.60 Million (-10.25% CAGR).
Index Memberships
Optipharm.CO.LTD is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.02% | #693 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.02% | #693 of 1384 |
Weight: Optipharm.CO.LTD's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Optipharm.CO.LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Optipharm.CO.LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Optipharm.CO.LTD's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $91.36 Million | $13.96 Billion | -$604.46 Million | 0.01x | N/A |
| 2019 | $89.87 Million | $13.65 Billion | -$655.33 Million | 0.01x | N/A |
| 2020 | $151.11 Million | $13.05 Billion | -$2.35 Billion | 0.01x | N/A |
| 2021 | $93.55 Million | $14.26 Billion | -$3.08 Billion | 0.01x | N/A |
| 2022 | $69.69 Million | $16.01 Billion | -$2.04 Billion | 0.00x | N/A |
| 2023 | $69.89 Million | $17.37 Billion | -$2.44 Billion | 0.00x | N/A |
| 2024 | $46.18 Million | $19.64 Billion | -$2.36 Billion | 0.00x | N/A |
Competitor Companies of 153710 by Market Capitalization
Companies near Optipharm.CO.LTD in the global market cap rankings as of May 5, 2026.
Key companies related to Optipharm.CO.LTD by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Optipharm.CO.LTD Historical Marketcap From 2018 to 2026
Between 2018 and today, Optipharm.CO.LTD's market cap moved from $91.36 Million to $ 51.60 Million, with a yearly change of -10.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩51.60 Million | +1.76% |
| 2025 | ₩50.70 Million | +9.80% |
| 2024 | ₩46.18 Million | -33.93% |
| 2023 | ₩69.89 Million | +0.29% |
| 2022 | ₩69.69 Million | -25.50% |
| 2021 | ₩93.55 Million | -38.09% |
| 2020 | ₩151.11 Million | +68.14% |
| 2019 | ₩89.87 Million | -1.63% |
| 2018 | ₩91.36 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Optipharm.CO.LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $51.60 Million USD |
| MoneyControl | $51.60 Million USD |
| MarketWatch | $51.60 Million USD |
| marketcap.company | $51.60 Million USD |
| Reuters | $51.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more